FDA Grants Beam Therapeutics RMAT Designation for SCD Therapy

Rare Daily Staff

The U.S. Food and Drug Administration granted Beam Therapeutics Regenerative Medicine Advanced Therapy (RMAT) designation for BEAM‑101, the company’s experimental genetically modified cell therapy for the treatment of sickle cell disease, a rare blood disorder.

The designation supports the development and evaluation of regenerative medicines, including genetic therapies, that address serious or life-threatening diseases with unmet medical needs. RMAT designation provides opportunities for early interactions with the FDA to discuss potential surrogate or intermediate endpoints to support accelerated approval, organizational commitment from senior FDA staff, opportunities to participate in novel review and development programs, and the potential for both rolling review and priority review of a product’s future Biologics License Application.

Sickle cell disease (SCD), a severe inherited blood disorder, is caused by a single point mutation in the beta‑globin gene. This mutation produces an abnormal form of hemoglobin known as sickle hemoglobin (HbS), which aggregates into long, rigid molecules that bend red blood cells into a sickle shape under low-oxygen conditions. Sickled cells obstruct blood vessels and die prematurely, leading to anemia, severe pain, infections, stroke, organ failure, and early death.

BEAM‑101 is an experimental genetically modified cell therapy for the treatment of severe SCD. The one-time therapy consists of autologous CD34+ hematopoietic stem and progenitor cells  that have been base-edited in the promoter regions of the HBG1/2 genes and are administered via hematopoietic stem cell transplantation. The BEAM‑101 edit is designed to inhibit the transcriptional repressor BCL11A from binding to the promoter without disrupting BCL11A expression. This leads to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF), mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal hemoglobin. HbF is the predominant hemoglobin variant during fetal development and early life.

Beam previously announced that the FDA granted orphan drug designation to BEAM‑101 in June 2025, and the company plans to present updated data from the BEACON Phase 1/2 trial by the end of 2025.